EAM
ITCI

EFG Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

EFG Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-74,190
Closed -$6.2M – 196
2024
Q4 		$6.2M Buy
74,190
+37,061
+100% +$3.05M 0.85% 24
2024
Q3 		$2.72M Buy
37,129
+2,677
+8% +$201K 0.45% 86
2024
Q2 		$2.36M Buy
34,452
+163
+0.5% +$11.3K 0.41% 92
2024
Q1 		$2.37M Buy
34,289
+1,935
+6% +$133K 0.41% 93
2023
Q4 		$2.32M Sell
32,354
-804
-2% -$46.3K 0.44% 86
2023
Q3 		$1.73M Buy
33,158
+837
+3% +$48.8K 0.41% 84
2023
Q2 		$2.05M Sell
32,321
-1,912
-6% -$119K 0.44% 72
2023
Q1 		$1.85M Sell
34,233
-1,917
-5% -$92.7K 0.41% 80
2022
Q4 		$1.94M Sell
36,150
-1,214
-3% -$60.8K 0.43% 80
2022
Q3 		$1.74M Sell
37,364
-2,811
-7% -$147K 0.4% 91
2022
Q2 		$2.29M Buy
40,175
+1,450
+4% +$82.2K 0.48% 71
2022
Q1 		$2.37M Sell
38,725
-346
-0.9% -$18K 0.36% 88
2021
Q4 		$2.04M Buy
+39,071
New +$1.64M 0.27% 110

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

EFG Asset Management's ITCI Position: Q1 2025 in Review

EFG Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 74,190 shares — an estimated $6.2M sold.

EFG Asset Management first reported a position in ITCI in Q4 2021 and held it in 13 quarters. The position peaked at $6.2M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • EFG Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • EFG Asset Management sold 74,190 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $6.2M.
  • EFG Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 13 quarters.
  • EFG Asset Management's Intra-Cellular Therapies Inc. position peaked at $6.2M in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on EFG Asset Management's 13F filing for Q1 2025, filed 15 May 2025.